Ryan Flinn

5 days ago | managedhealthcareexecutive.com | Ryan Flinn

Currently just two gene therapies have been approved to treat retinal diseases: Luxturna (voretigene neparvovec-rzyl) approved in 2017 to treat inherited retinal diseases with two mutations of the RPE65 gene, and the more recently approved Encelto (revakinagene taroretcel-lwey) to treat the progressive eye disease macular telangiectasia type 2 (MacTel). But the broader field of gene therapy research for retinal diseases remains stuck in early phases, according to a new study.

1 week ago | managedhealthcareexecutive.com | Ryan Flinn

Patient advocates are creating an educational toolkit to help sickle cell disease patients better understand gene therapies that could potentially cure their condition, addressing a growing concern that complex science is preventing people from accessing life-changing treatments. The effort, spearheaded by Wunmi E. Bakare of Through The Pain Inc. and Christelle G.

1 week ago | open.substack.com | Ryan Flinn

This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

2 weeks ago | managedhealthcareexecutive.com | Ryan Flinn

A class of targeted therapies currently used to treat lung and other cancers may be effective for patients with a deadly form of drug-resistant melanoma, according to new research. The study, published in Cancer Research, examined tumor cells from 30 melanoma patients who did not respond to immunotherapy, discovering a genetic mutation commonly found in other cancers that do respond to a class of medications called EGFR inhibitors.

2 weeks ago | managedhealthcareexecutive.com | Ryan Flinn

Mobile apps that use AI to spot skin cancer can be fooled by something as simple as a transparent sticker on the camera, a new study shows, raising new concerns about patient safety and the reliability of these tools beyond their digital performance.